Literature DB >> 27019056

Malarial hepatopathy: Clinical profile and association with other malarial complications.

Anshika Jain1, Reshma Kaushik2, Rajeev Mohan Kaushik3.   

Abstract

This prospective study assessed the incidence, clinical profile and outcome of malarial hepatopathy and its association with other complications in patients with malaria, proved by peripheral blood smear examination and rapid malaria test. Hyperbilirubinemia (Serum bilirubin >3mg/dL) with >3-fold rise in serum aminotransferases in absence of a different explanation for such derangement was considered as malarial hepatopathy. Of 134 (falciparum-81, vivax-48 and mixed falciparum and vivax-5) malaria cases, hyperbilirubinemia occurred in 41.04%. Serum aspartate aminotransferase (AST) was raised >3-fold in 17.16% and serum alanine aminotransferase (ALT) in 4.47% cases. Malarial hepatopathy was observed in 4.47% (falciparum-5 and vivax malaria-1) cases, but had insignificant association with the type of malaria (p=0.532). Serum bilirubin, AST and ALT levels were higher while age was lower in both overall (p<0.05 each) and falciparum malaria cases with hepatopathy than without hepatopathy (p<0.05 each). Malarial hepatopathy was associated with a higher incidence of cerebral malaria, shock, acute respiratory distress syndrome (ARDS) and acute kidney injury in both overall (p<0.05 each) and falciparum malaria (p<0.05 each) and hyponatremia and disseminated intravascular coagulation only in overall malaria (p<0.05). Malarial hepatopathy had significant association with duration of hospitalization, parasite clearance time, fever clearance time and jaundice clearance time in overall (p<0.05 each) and falciparum (p<0.05 each) but not vivax malaria cases (p>0.05 each). Mortality occurred in 1 (20%) case of falciparum-induced hepatopathy with an overall mortality of 16.66%. ARDS (p=0.003) and shock (p=0.026) were independently associated with malarial hepatopathy overall while only ARDS with falciparum-induced hepatopathy (p=0.006). Thus, hepatocellular dysfunction is common in malaria but that qualifying as malarial hepatopathy is not common. Malarial hepatopathy is likely to occur in presence of other malarial complications. It is an epiphenomenon in severe malaria and indicative of severe disease. Establishing a particular association with malaria or mortality would require a larger case-control study of severe malaria.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical profile; Complications; Hepatopathy; India; Malaria; Outcome

Mesh:

Substances:

Year:  2016        PMID: 27019056     DOI: 10.1016/j.actatropica.2016.03.031

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  16 in total

1.  Case Report: Severe Plasmodium vivax Malaria Mimicking Sepsis in a Neonate.

Authors:  Suryadi N N Tatura; Elizabeth Clarissa Wowor; Jose M Mandei; Rocky Wilar; Sarah M Warouw; Johnny Rompis; Priscilla Kalensang; Joseph Tuda
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

Review 2.  Respiratory Complications of Plasmodium vivax Malaria: Systematic Review and Meta-Analysis.

Authors:  Fernando Val; Kim Machado; Lisiane Barbosa; Jorge Luis Salinas; André Machado Siqueira; Maria Graças Costa Alecrim; Hernando Del Portillo; Quique Bassat; Wuelton Marcelo Monteiro; Marcus Vinícius Guimarães Lacerda
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

Review 3.  Adjunctive therapy for severe malaria: a review and critical appraisal.

Authors:  Rosauro Varo; Valerie M Crowley; Antonio Sitoe; Lola Madrid; Lena Serghides; Kevin C Kain; Quique Bassat
Journal:  Malar J       Date:  2018-01-24       Impact factor: 2.979

4.  Differential induction of malaria liver pathology in mice infected with Plasmodium chabaudi AS or Plasmodium berghei NK65.

Authors:  Diletta Scaccabarozzi; Katrien Deroost; Yolanda Corbett; Natacha Lays; Paola Corsetto; Fausta Omodeo Salè; Philippe E Van den Steen; Donatella Taramelli
Journal:  Malar J       Date:  2018-01-09       Impact factor: 2.979

5.  Are respiratory complications of Plasmodium vivax malaria an underestimated problem?

Authors:  Fernando Val; Sara Avalos; André Alexandre Gomes; José Evelio Albornoz Zerpa; Gustavo Fontecha; André Machado Siqueira; Quique Bassat; Maria Graças Costa Alecrim; Wuelton Marcelo Monteiro; Marcus Vinícius Guimarães Lacerda
Journal:  Malar J       Date:  2017-12-22       Impact factor: 2.979

6.  Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria.

Authors:  Rosauro Varo; Valerie M Crowley; Antonio Sitoe; Lola Madrid; Lena Serghides; Rubao Bila; Helio Mucavele; Alfredo Mayor; Quique Bassat; Kevin C Kain
Journal:  Malar J       Date:  2017-05-23       Impact factor: 2.979

7.  The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study.

Authors:  John Woodford; G Dennis Shanks; Paul Griffin; Stephan Chalon; James S McCarthy
Journal:  Am J Trop Med Hyg       Date:  2018-02-08       Impact factor: 2.345

8.  Liver Injury in Uncomplicated Malaria is an Overlooked Phenomenon: An Observational Study.

Authors:  Isaie J Reuling; Gerdie M de Jong; Xi Zen Yap; Muhammad Asghar; Jona Walk; Lisanne A van de Schans; Rob Koelewijn; Anna Färnert; Quirijn de Mast; Andre J van der Ven; Teun Bousema; Jaap J van Hellemond; Perry J J van Genderen; Robert W Sauerwein
Journal:  EBioMedicine       Date:  2018-09-19       Impact factor: 8.143

9.  Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission.

Authors:  Paul Griffin; Cielo Pasay; Suzanne Elliott; Silvana Sekuloski; Maggy Sikulu; Leon Hugo; David Khoury; Deborah Cromer; Miles Davenport; Jetsumon Sattabongkot; Karen Ivinson; Christian Ockenhouse; James McCarthy
Journal:  PLoS Negl Trop Dis       Date:  2016-12-08

Review 10.  Endothelial Activation: The Ang/Tie Axis in Sepsis.

Authors:  Aleksandra Leligdowicz; Melissa Richard-Greenblatt; Julie Wright; Valerie M Crowley; Kevin C Kain
Journal:  Front Immunol       Date:  2018-04-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.